Abstract:Motivated by increasing pressure for decision makers to shorten the time required to evaluate the efficacy of a treatment such that treatments deemed safe and effective can be made publicly available, there has been substantial recent interest in using an earlier or easier to measure surrogate marker, $S$, in place of the primary outcome, $Y$. To validate the utility of a surrogate marker in these settings, a commonly advocated measure is the proportion of treatment effect on the primary outcome that is explained by the treatment effect on the surrogate marker (PTE). Model based and model free estimators for PTE have also been developed. While this measure is very intuitive, it does not directly address the important questions of how $S$ can be used to make inference of the unavailable $Y$ in the next phase clinical trials. In this paper, to optimally use the information of surrogate S, we provide a framework for deriving an optimal transformation of $S$, $g_{opt}(S)$, such that the treatment effect on $g_{opt}(S)$ maximally approximates the treatment effect on $Y$ in a certain sense. Based on the optimally transformed surrogate, $g_{opt}(S)$, we propose a new measure to quantify surrogacy, the relative power (RP), and demonstrate how RP can be used to make decisions with $S$ instead of $Y$ for next phase trials. We propose nonparametric estimation procedures, derive asymptotic properties, and compare the RP measure with the PTE measure. Finite sample performance of our estimators is assessed via a simulation study. We illustrate our proposed procedures using an application to the Diabetes Prevention Program (DPP) clinical trial to evaluate the utility of hemoglobin A1c and fasting plasma glucose as surrogate markers for diabetes.

Information Recovery in a Study with Surrogate Endpoints

Surrogate Aided Unsupervised Recovery of Sparse Signals in Single Index Models for Binary Outcomes

Improving Semiparametric Estimation by Using Surrogate Data

Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm

Estimation in Autoregressive Models with Surrogate Data and Validation Data

Empirical Likelihood Inference in Nonlinear Errors-in-Covariables Models With Validation Data

On the Evaluation of Surrogate Markers in Real World Data Settings

Nonparametric Check for Partial Linear Errors-In-Covariables Models with Validation Data

A Reflection on the Impact of Misspecifying Unidentifiable Causal Inference Models in Surrogate Endpoint Evaluation

On the role of surrogates in the efficient estimation of treatment effects with limited outcome data

Evaluating Surrogate Marker Information using Censored Data

Semiparametric estimation of the nonmixture cure model with auxiliary survival information

Estimating Treatment Effects using Multiple Surrogates: The Role of the Surrogate Score and the Surrogate Index

Statistical Inference with Nonignorable Non-Probability Survey Samples

Generalized Linear Models with Covariate Measurement Error and Zero-Inflated Surrogates

A general, simple, robust method to account for measurement error when analyzing data with an internal validation subsample

A Model for Adjusting for Nonignorable Verification Bias in Estimation of the ROC Curve and Its Area with Likelihood‐Based Approach

Double robust estimation of functional outcomes with data missing at random

Asymptotically Pivotal Statistic for Surrogate Testing with Extended Hypothesis

Towards Optimal Use of Surrogate Markers to Improve Power

Two-step estimators in partial linear models with missing response variables and error-prone covariates